The impact of hypoglycemia on healthcare costs: a modeling study from Chile

• Published in: Expert review of pharmacoeconomics & outcomes research Vol. 22; no. 1; p. 101
• Main Authors: Balmaceda, Carlos, Espinoza, Manuel A, Cabieses, Baltica, Espinoza, Nazareth
• Format: Journal Article
• Language: English
• Published: England 02.01.2022
• Subjects: Chile; Diabetes Mellitus, Type 2 - drug therapy; Health Care Costs - statistics & numerical data; Humans; Hypoglycemia - economics; Hypoglycemic Agents - therapeutic use; Insulin - therapeutic use; Chile; Type 2 diabetes; cost analysis; chile; hypoglycemia
• ISSN: 1744-8379
• DOI: 10.1080/14737167.2021.1865808

This study aimed to estimate the expected cost of hypoglycemia in Diabetes Mellitus type-2 patients receiving hypoglycemic treatment in Chile and to explore the effect of the potential reduction of hypoglycemia over the total cost incurred by its public health system. A cost analysis was carried out based on a state transition mathematical model. The model used microsimulation with data from the National Health Survey 2016-2017 in Chile. Costs included follow-up, in-hospital and ambulatory care. Separate analysis was conducted for patients treated with insulin, or sulfonylurea. The annual expected total cost of hypoglycemia estimated for the Chilean public system was USD 288,922,523 (USD 273 per patient). The subgroup treated with insulin reached USD 353 per patient whereas the sulfonylurea subgroup was USD 217 per patient. The analysis revealed that for every 1% reduction of the incidence rate of severe hypoglycemia the cost is reduced 0.79% in total, 0.59% for the insulin subgroup, and 0.95% for the sulfonylurea subgroup. The cost of hypoglycemia represents a high proportion of the public health budget in Chile, being similar to those resources allocated to provide coverage of diabetic treatments through its universal health benefit plan. DM2: type 2 diabetes mellitus; RR: relative risk; ENS: national health survey in Chile.